Looking to sell Seaport Therapeutics stock or options?
Seaport Therapeutics is focused on creating new neuropsychiatric medications targeting areas with significant unmet patient needs. Their treatments are designed for oral bioavailability, which avoids first-pass metabolism and minimizes liver toxicity and other adverse effects, thereby improving the quality of life for individuals with neuropsychiatric disorders.
CPP Investments, Gray's Creek Capital Partners, Foresite Capital, Hawktail, T. Rowe Price Group, Third Rock Ventures, Sofinnova Investments, The Invus Group, Goldman Sachs Asset Management, PureTech Health, ARCH Venture Partners, General Atlantic.